Johnson & Johnson is committing up to $60 million for global rights to a Nanobiotix therapy that enhances radiation treatment for head and neck cancer. A Phase 3 test of the nanoparticle-based therapy is expected to yield preliminary data in 2024.
Bausch + Lomb is acquiring Johnson & Johnson’s Blink line of eye drops. The deal comes as J&J exits the consumer business while Bausch + Lomb expands its product portfolio with its second deal in as many weeks.
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Johnson & Johnson’s oral psoriasis drug met the goals of a mid-stage clinical study, and the pharma giant now plans to advance the twice-daily pill to Phase 3 testing. J&J is one of several biopharmaceutical companies developing pill alternatives to biologic drugs that are injected or infused.
Johnson & Johnson is acquiring rights to two next-generation cell therapies from Cellular Biomedicines, both potential treatments for diffuse large B-cell lymphoma. One therapy is already in the clinic while the other is on track to begin human testing this year.
Johnson & Johnson’s pullback from RSV research thins the pack of companies aiming to develop a vaccine for the pathogen. GSK and Pfizer have vaccines under FDA review and a shot from Moderna could soon follow.
A Johnson & Johnson drug acquired as part of a $6.5 billion deal has preliminary data showing it met the main goal of a mid-stage test in a rare blood disorder that can become fatal to fetuses. Full data from the trial will be presented at a future scientific meeting.
At the Payer Insights sessions on Day 1 of ViVE 2024, a panel on prior authorization offered compelling insights from speakers who shared the positive developments in this area after years of mounting frustration. Speakers also shared challenges as they work with providers to figure out how policy developments and technology will work in practice.
Johnson & Johnson is stopping clinical development of an experimental HIV vaccine after the four-shot regimen did not beat a placebo in a late-stage study. The clinical trial failure comes follows the 2021 failure of the vaccine candidate in a different study population.
Johnson & Johnson's CEO believes the company will maintain its strong reputation for innovation amid changing economic conditions because of its hefty investments in research and development. He said it's crucial to invest both internally and externally, as some of the most innovative and lucrative opportunities come from outside companies.
Johnson & Johnson is seeking FDA approval of a multiple myeloma drug that could become the first one addressing a novel target called GPRC5D. Data from the Phase 1/2 study supporting the biologics license application were presented in New Orleans during the annual meeting of the American Society of Hematology.
FDA approval of Tecvayli, from Johnson & Johnson subsidiary Janssen Biotech, makes it the newest therapy that treats multiple myeloma by targeting the cancer protein BCMA. Though this off-the-shelf drug offers patients a more convenient dosing option, it comes with similar complication risks as other biologics approved for this type of blood cancer.
In an era of escalating healthcare costs and a growing preference for natural, holistic approaches to health, The Impact Brands emerges as a collective of diverse brands dedicated to supporting overall wellness through natural means.
Breast cancer drugs and cell therapies were prominent in this year’s annual meeting of the American Society of Clinical Oncology. Here’s a recap of some of the news highlights from the biggest cancer conference of the year.
The FDA amended emergency authorization of Johnson & Johnson’s Covid-19 vaccine. In other regulatory news this past week, drug approvals include a cancer drug that converted its accelerated regulatory approval to a full regulatory nod, while several companies dealt with rejections or clinical trial setbacks.
The FDA approved Johnson and Johnson Vision Care's Acuvue Theravision with the antihistamine Ketotifen to treat allergy-induced itchy eyes for contact lens wearers.
Research of Johnson & Johnson’s baby powder included a prison study in which inmates, mostly Black men, were injected with asbestos. The study was intended to assess how asbestos’s effects on the skin compare to talc, the key component of baby powder.
The FDA approved drugs from Johnson & Johnson and CTI BioPharma in the past week. Complete response letters were issued to Gilead Sciences, Amryt, and Reata Pharmaceuticals.